In a patient with three months of amenorrhea, a negative urine pregnancy test, and who has been taking dienogest 2 mg daily for one month, can I use a combined oral contraceptive containing ethinyl estradiol (EE) with dienogest (DNG)?

Yes, you can use a combined oral contraceptive containing ethinyl estradiol with dienogest in this patient.

In a patient with amenorrhea who has been taking dienogest 2 mg daily for one month with a negative pregnancy test, you can safely initiate a COC containing ethinyl estradiol (EE) and dienogest (DNG). The key is ensuring pregnancy is reasonably excluded before starting, which has been done 1.

Initiation Protocol

Since this patient has amenorrhea (not postpartum):

• Start the COC at any time once pregnancy is reasonably excluded 1
• Require backup contraception (condoms or abstinence) for the next 7 days 1
• The patient does not need to wait for withdrawal bleeding to start the COC

Regarding the Dienogest Transition

The patient has been taking dienogest 2 mg daily for one month. When transitioning to a COC containing EE/DNG:

• Simply stop the dienogest-only therapy and start the COC
• The 7-day backup contraception rule still applies since she's amenorrheic
• No washout period is needed between progestin-only therapy and COC initiation

EE/DNG Combination: Evidence Base

The combination of ethinyl estradiol 30 μg with dienogest 2 mg is well-established and widely used. This formulation has been available since 1995 and is the most commonly prescribed oral contraceptive in Germany 2. The evidence demonstrates:

• Reliable contraceptive efficacy with a Pearl Index of 0.198-0.489 2, 3, 4
• Effective cycle control with reduced menstrual bleeding intensity and duration 2, 4
• Antiandrogenic benefits improving acne, skin greasiness, and hirsutism 2, 4, 5
• Good tolerability with adverse events (breast tenderness, headache, nausea) that decrease over time 2, 4

Alternative Formulations

While EE 30 μg/DNG 2 mg is the standard formulation, newer evidence suggests that COCs containing 17β-estradiol (E2) or estetrol (E4) with dienogest may offer advantages over ethinyl estradiol-based formulations 6:

• E2-based COCs (E2/DNG or E2 valerate/DNG) are recommended as first choice when contraception is required in specific populations 6
• Lower VTE risk: E2 valerate/DNG shows significantly decreased VTE risk compared to EE/levonorgestrel (HR 0.46,95% CI 0.22-0.98) 7
• Better pain control: E2-containing COCs show greater improvement in endometriosis-associated pain than EE-containing COCs 8

However, EE/DNG remains a second-choice option and is perfectly acceptable for standard contraceptive use 6.

Clinical Considerations

Common pitfalls to avoid:

1. Don't wait for menstrual bleeding to start the COC in amenorrheic patients—this delays contraceptive protection unnecessarily
2. Don't forget the 7-day backup rule for amenorrheic patients, regardless of prior progestin use
3. Counsel about breakthrough bleeding, especially in the first 3-6 months, which is common but not harmful 1
4. Consider extended or continuous regimens if the patient prefers to avoid monthly bleeding 3—EE 30 μg/DNG 2 mg can be used in 84/7 day cycles with good efficacy and tolerability

Monitoring

• Reassure the patient that irregular bleeding in the first 3-6 months is normal and decreases with continued use 1
• If unscheduled bleeding persists and is unacceptable, consider switching to an E2-based formulation or alternative contraceptive method 1
• The patient should contact you if she misses pills, as specific backup contraception protocols apply based on timing and number of missed pills 9, 10